Meitheal Pharmaceuticals
↗Chicago, Illinois, United States
Meitheal Pharmaceuticals is an agile biopharmaceutical company headquartered in Chicago, Illinois, dedicated to simplifying access to life-changing medicines through generic injectable products and specialty biopharmaceuticals. Founded in 2017 by Tom Shea and initially focused on generic injectables, the company has expanded its portfolio to include biologics, biosimilars, fertility products, and branded pharmaceuticals. The company's mission, inspired by the Irish tradition of 'meitheal' (working together for the greater good), emphasizes sustainable generics development and consistent supply of fairly-priced pharmaceutical products. Operating as the exclusive US commercialization arm of its parent company Nanjing King-Friend Biochemical Pharmaceutical Company, Meitheal combines manufacturing expertise with commercial acumen to bring generic and specialty drugs to market.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:Not publicly disclosed
Founded:2017
Ownership:private
Status:operating
FUNDING
Stage:Growth Stage
Total Raised:$80M
Investors:Nanjing King-Friend Biochemical Pharmaceutical Company (majority stake), LYFE Capital, JP Morgan (debt financing 2023)
PIPELINE
Stage:Phase 1-3 and Commercial
Lead Drug Stage:Commercial (multiple approved products)
Modalities:Small molecule generics, Injectable formulations, mAb/Biosimilars, Branded specialty drugs
Active Trials:4
Trial Phases:Phase 2: 1 | Phase 3: 2 | Phase 4: 1
FDA Approvals:60
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Nanjing King-Friend Biochemical Pharmaceutical Company, Ltd. (NKF)
Key Partnerships:Nanjing King-Friend Biochemical Pharmaceutical Company - parent company and major capital investor, Hong Kong King-Friend Industry Co., Ltd. - supply and licensing partner, Nabriva Therapeutics - acquisition of CONTEPO (fosfomycin IP), Multiple biosimilar manufacturing partners for oncology and fertility products
COMPETITION
Position:Challenger
Competitors:Slate Run Pharmaceuticals, Slayback Pharma, Avet Pharmaceuticals, Xiromed, Somerset Pharma, Baxter, Hospira, Teva (generic injectables division)
LEADERSHIP
Key Executives:
Tom Shea - CEO and Founder
Jennifer Mokos - Executive Vice President of Operations
Dr. Lonnie Brent - Senior Vice President of Medical Affairs
Dr. Keith Robinson - Chief Medical Officer
Shakuntala Maharaj - Senior Vice President, Quality
Scientific Founders:Tom Shea - Founder/CEO with pharmaceutical industry background
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Meitheal Pharmaceuticals and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Meitheal Pharmaceuticals. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.